Osteoteri (Teriparatide)

Teriparatide, the active ingredient in Osteoteri, is a parathyroid hormone analog presented as an injection for subcutaneous use. It treats osteoporosis in postmenopausal women and patients receiving long‑term glucocorticoid therapy. GNH USA supplies Osteoteri as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Osteoteri as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Osteoteri is a parathyroid hormone analog that acts on bone remodeling pathways to improve skeletal strength.

- Postmenopausal osteoporosis: increases bone mineral density and reduces fracture risk. - Glucocorticoid‑induced osteoporosis: promotes bone formation to counteract steroid‑related bone loss. - Severe osteoporosis at high risk of fracture: helps achieve greater bone mass when other therapies are insufficient.

Teriparatide may cause a range of adverse reactions, most of which are mild to moderate in intensity.

Common Side Effects: - Nausea: occasional upset stomach or feeling of queasiness. - Headache: mild to moderate head pain. - Dizziness: transient light‑headedness. - Injection‑site reactions: redness, swelling or bruising at the injection site. - Hypercalcaemia: elevated blood calcium levels, usually mild.

Serious or Rare Side Effects: - Osteosarcoma: a very rare bone cancer observed in animal studies. - Severe hypercalcaemia: markedly high calcium that may require medical intervention. - Hypersensitivity reactions: rash, itching, or anaphylaxis in rare cases. - Cardiovascular events: rare reports of hypertension or arrhythmia. - Persistent leg pain: unexplained, ongoing discomfort in the lower limbs.

Before starting Osteoteri, clinicians should assess patient history, laboratory values and risk factors.

- Contraindication: patients with a history of osteosarcoma or skeletal metastases. - Monitoring: regular serum calcium and vitamin D levels during therapy. - Duration limit: treatment should not exceed 24 months to minimise long‑term risk. - Pregnancy and lactation: avoid use unless the potential benefit outweighs risk. - Renal function: adjust evaluation for patients with severe kidney impairment. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Teriparatide may interact with other medicines that affect calcium metabolism or bone turnover.

Major Interactions (Avoid): - Bisphosphonates: concurrent use can blunt the anabolic effect of teriparatide. - Calcium supplements high‑dose: may reduce drug absorption when taken simultaneously.

Moderate Interactions (Monitor Closely): - Vitamin D analogues (calcitriol): may increase risk of hypercalcaemia. - Loop diuretics: can potentiate calcium elevation. - Corticosteroids: may require closer monitoring of bone markers. - Anticonvulsants (phenytoin, phenobarbital): may alter vitamin D metabolism affecting calcium balance.